Table 2 Clinical performance of cervical cancer screening methods/tools for detecting CIN2+
Author, year of publication | Screening method/tool | HIV-infected | HIV-negative | ||||||
|---|---|---|---|---|---|---|---|---|---|
Sensitivity | Specificity | PPV | NPV | Sensitivity | Specificity | PPV | NPV | ||
Bansil et al., 2015 | VIA | 77.1 (59.9–89.6) | 47.3 (40.8–53.8) | 17.8 (12.0–24.8) | 93.3 (87.3–97.1) | 93.8 (69.8–99.8) | 60.5 (57.3–63.7) | 3.9 (2.2–6.4) | 99.8(99.0–100.0) |
Chung et al., 2013 | VIA | 62.7 (53.4–71.2) | 65.9 (60.7–70.7) | 37.1 (30.5–44.2) | 84.6 (79.8–88.5) |  |  |  |  |
Dartell et al., 2014 | VIA | 50.0 (31.5–68.5) | 90.5 (87.2–93.8) | 32.6 | 95.2 | 22.9 (14.5–31.3) | 97.2 (96.7–97.8) | 21.6 | 97.5 |
Huchko et al., 2015 | VIA | 84.0 (64.0–95.5) | 78.6 (73.5–83.1) | 24.7 (16.0–35.3) | 98.3 (95.8–99.5) |  |  |  |  |
Joshi et al., 2013 | VIA | 83.6 (71.2–92.2) | 88.8 (86.7–90.6) | 27.7 (21.1–35.2) | 99.1 (98.2–99.6) |  |  |  |  |
Kuhn et al., 2010 | VIA | 63.9 (46.2–79.2) | 73.5 (67.4–78.8) | 27.5 (17.8–37.3) | 90.9 (85.8–96.0) | 47.8 (35.7–60.2) | 80.3 (78.2–82.2) | 9.6 (6.5–12.7) | 96.7 (95.6–97.8) |
Mabeya et al., 2012 | VIA | 69.6 | 51.0 | 38.6 | 79.1 | Â | Â | Â | Â |
Sahasrabuddhe et al., 2012 | VIA | 80.0 (66.3–90.0) | 82.6 (77.4–87.1) | 47.6 (36.6–58.9) | 95.4 (91.8–97.8) |  |  |  |  |
Akinwuntan et al., 2008 | VIA | 76.0 (52.0–91.0) | 83.0 (77.0–88.0) | 34.0 (21.0–49.0) | 97.0 (92.0–99.0) |  |  |  |  |
Firnhaber et al., 2016 | VIA | 65.4 (59.7–71.1) | 68.5 (65.3–71.7) |  |  |  |  |  |  |
Chibwesha et al., 2016 | VIA | 48.0 (30.0–67.0) | 92.0 (86.0–95.0) | 52.0 (33.0–71.0) | 91.0 (85.0–95.0) |  |  |  |  |
Huchko et al., 2015 | VILI | 84.2 (68.7–94.0) | 76.4 (71.2–81.3) | 31.7 (22.8–41.7) | 97.4 (94.4–99.0) |  |  |  |  |
Joshi et al., 2013 | VILI | 89.1 (77.8–95.9) | 89.3 (87.3–91.1) | 30.1 (23.1–37.7) | 99.4 (98.6–99.8) |  |  |  |  |
Chibwesha et al., 2016 | DC | 59.0 (41.0–76.0) | 88.0 (82.0–93.0) | 49.0 (32.0–65.0) | 92.0 (87.0–96.0) |  |  |  |  |
Bateman et al., 2014 | DC | 84.0 (72.0–91.0) | 58.0 (52.0–64.0) | 33.0 (26.0–41.0) | 93.0 (88.0–96.0) |  |  |  |  |
Joshi et al., 2013 | Pap smear | 63.3 (48.3–76.6) | 94.5 (92.9–95.8) | 35.2 (25.3–46.1) | 98.2 (97.2–98.9) |  |  |  |  |
Chung et al., 2013 | Pap smear | 71.8 (62.8–79.4) | 97.1 (94.7–98.4) | 88.8 (80.5–93.8) | 91.5 (88.2–93.9) |  |  |  |  |
Mabeya et al., 2013 | Pap smear | 52.5 | 66.3 | 39.7 | 76.8 | Â | Â | Â | Â |
Sahasrabuddhe et al., 2012 | Pap smear | 60.5 (44.4–75.0) | 64.6 (57.9–70.8) | 24.8 (16.9–34.1) | 89.4 (83.6–93.7) |  |  |  |  |
Akinwuntan et al., 2008 | Pap smear | 57.0 (34.0–77.0) | 95.0 (90.0–97.0) | 55.0 (33.0–75.0) | 95.0 (91.0–98.0) |  |  |  |  |
Firnhaber et al., 2013 | Pap smear | 75.8 (70.8–80.8) | 83.4 (80.9–85.9) |  |  |  |  |  |  |
Bateman et al., 2014 | Pap smear | 61.0 (48.0–72.0) | 58.0 (52.0–64.0) | 27.0 (20.0–35.0) | 86.0 (79.0–90.0) |  |  |  |  |
Michelow et al., 2016 | Cellslide® automated liquid-based cytology | 76.0 (64.8–85.1) | 91.0 (87.0–94.2) | 70.4 (59.2–80.0) | 93.1 (89.4–95.9) |  |  |  |  |
Bansil et al., 2015 | Vaginal careHPV | 80.0 (63.1–91.6) | 59.9 (53.4–66.2) | 22.8 (15.7–31.2) | 95.3 (90.6–98.1) | 75.0 (47.6–92.7) | 81.9 (79.3–84.4) | 6.7 (3.5–11.4) | 99.5 (98.7–99.9) |
Bansil et al., 2015 | Cervical careHPV | 94.3 (80.8–99.3) | 62.4 (55.9–68.6) | 27.0 (19.4–35.8) | 98.7 (95.3–99.8) | 81.3 (54.4–96.0) | 80.9 (78.2–83.3) | 6.8 (3.7–11.4) | 99.6 (98.8–99.9) |
Obiri-Yeboah et al., 2017 | CareHPV | 87.5 (47.3–99.7) | 52.1 (44.7–59.5) | 7.2 (3.0–14.3) | 99.0 (94.5–100.0) |  |  |  |  |
Segondy et al., 2016 [36] | CareHPV | 93.3 (83.8–98.2) | 57.9 (54.5–61.2) |  |  |  |  |  |  |
Chung et al., 2013 | HPV DNA test | 83.6 (75.6–89.4) | 55.7 (50.4–60.9) | 37.7 (31.9–43.9) | 91.4 (86.8–94.5) |  |  |  |  |
Dartell et al., 2014 | HR HPV | 100.0 | 58.2 (52.6.63.7) | 17.9 | 100.0 | 92.7 (87.5–97.9) | 85.3 (84.0–86.6) | 17.2 | 99.7 |
Joshi et al., 2013 | HC2 test | 94.6 (84.9–98.9) | 77.4 (74.8–79.9) | 17.8 (13.6–22.6) | 99.6 (99.0–99.9) |  |  |  |  |
Ngou et al., 2015 | HC2 | 88.8 | 55.2 | 24.7 | 96.7 | Â | Â | Â | Â |
Ngou et al., 2015 | INNO-LiPA | 92.5 | 35.1 | 19.1 | 96.6 | Â | Â | Â | Â |
Obiri-Yeboah et al., 2017 | Anyplex II HPV 28 | 87.5 (47.3–99.7) | 38.8 (31.8–46.2) | 5.7 (2.3–11.5) | 98.6 (92.7–100.0) |  |  |  |  |
Firnhaber et al., 2016 | HC2 | 91.9 (88.5–95.3) | 51.4 (48.0–54.8) |  |  |  |  |  |  |
Chibwesha et al., 2016 | Xpert HPV | 88.0 (71.0–97.0) | 60.0 (52.0–86.0) | 30.0 (21.0–40.0) | 96.0 (90.0–99.0) |  |  |  |  |
Chibwesha et al., 2016 | OncoE6 | 31.0 (16.0–50.0) | 99.0 (97.0–100) | 91.0 (59–100) | 88.0 (83.0–93.0) |  |  |  |  |
Segondy et al., 2016 | INNO-LiPA | 96.7 (88.5–99.6) | 32.0 (29.0–35.2) |  |  |  |  |  |  |
Kuhn et al., 2010 | HPV DNA | 94.4 (81.3–99.3) | 64.4 (58.0–70.3) | 29.9 (21.3–38.6) | 97.2 (87.0–99.4) | 87.0 (76.7–93.9) | 87.0 (85.2–88.6) | 22.7(17.6–27.9) | 99.0 (97.9–99.5) |
Wu et al., 2016 | P16INK4a cutoff level = 9 U/mL (%) | 89.0 | 22.9 | 13.6 | 93.8 |  |  |  |  |
Chung et al., 2013 | VIA + HPV test | 58.2 (48.8–67.0) | 83.7 (79.4–87.2) | 53.3 (44.4–62.0) | 86.2 (82.1–89.5) |  |  |  |  |
Chung et al., 2013 | VIA + Pap smear | 50.9 (41.7–60.1) | 99.1 (97.5–99.7) | 94.9 (86.1–98.3) | 86.3 (82.5–89.3) |  |  |  |  |
Chung et al., 2013 | HPV + Pap smear | 62.7 (53.4–71.2) | 98.5 (96.6–99.4) | 93.2 (85.1–97.1) | 89.2 (85.7–91.9) |  |  |  |  |
Joshi et al., 2013 | VIA and VILI | 81.8 (69.1–90.9) | 93.2 (91.5–94.6) |  |  |  |  |  |  |
Joshi et al., 2013 | HC2 and VIA | 80.0 (67.0–89.6) | 96.0 (94.6–97.1) |  |  |  |  |  |  |
Joshi et al., 2013 | HC2 and VILI | 83.6 (71.2–92.2) | 96.9 (95.7–97.9) |  |  |  |  |  |  |
Joshi et al., 2013 | HC2 and VIA/VILI | 85.5 (73.3–93.5) | 95.3 (93.9–96.5) |  |  |  |  |  |  |
Joshi et al., 2013 | VIA and cytology | 57.1 (42.2–71.2) | 98.8 (98.0–99.4) |  |  |  |  |  |  |
Joshi et al., 2013 | VILI and cytology | 55.1 (40.2–69.3) | 99.6 (99.0–99.9) |  |  |  |  |  |  |
Joshi et al., 2013 | HC2 and cytology | 63.3 (48.3–76.6) | 96.6 (95.3–97.6) |  |  |  |  |  |  |